A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 446 participants.

Also called NCT05301712

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 446 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05301712
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05301712. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-07 (actual); primary completion 2022-10-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
Condition
Stroke, Acute
Intervention (Drug)
Naloxone hydrochloride 5.0mg/5ml
Intervention (Drug)
Sodium Chloride 45mg/5ml
Lead sponsor
Samjin Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05301712
Content hash
0fe8d923dfa6a97db6e06d2e93d75951d381631e768626d06ad6a8245c3cfb2c